Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Novartis AG NVS announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna. The program comprised two open-label trials – ENESTfreedom and ENESTop – that evaluated Tasigna’s potential of maintaining molecular response (MR) after stopping therapy in the chronic phase in adult patients suffering from Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In the ENESTfreedom trial, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment. […]